Business Wire

Canoga Perkins Launches Private 5G with TSN Demo, Showcasing a Streamlined way to Deploy Private 5G for Industrial and Enterprise Use Cases

Share

Network connectivity solutions provider, Canoga Perkins today announces the launch of its Private 5G with Time-Sensitive Networking (TSN) demonstration in its Customer Experience Center (CEC). This demo serves as a model for how Private 5G should be deployed, offering a streamlined, reliable, and secure approach for industrial and enterprise applications.

The setup integrates the Moso Canopy 5GID2 radio and Canoga Perkins’ switch and transport solution, SyncMetra, creating a comprehensive, best-in-class Private 5G solution. The combination of these technologies simplifies the deployment process, reduces complexity, and ensures high performance for mission-critical applications.

“Private 5G has the potential to revolutionize industrial and enterprise connectivity, but only if deployed correctly,” said Malik Arshad, CEO of Canoga Perkins. “With this demonstration, we are showcasing a proven, scalable, and secure approach that enterprises can adopt with confidence. By leveraging Moso’s high-performance radios and our SyncMetra transport solution, we have created an architecture that eliminates common deployment hurdles.”

“Private 5G adoption is accelerating, particularly in industrial and enterprise sectors looking for greater control and reliability,” said Stephen Leotis, CEO of Moso Networks. “We share Canoga Perkins’ vision of purpose-built solutions that address the specific needs of these industries. By integrating our advanced radio technology with their transport expertise, we’re helping enterprises transition to Private 5G in a way that is seamless, scalable, and future-ready.” Moso Networks, a key partner in this initiative, provides cutting-edge radios that ensure reliable and efficient wireless connectivity.

Canoga Perkins invites enterprises and industry leaders to experience this live Private 5G with TSN demo firsthand at its lab. The demonstration provides a real-world example of how organizations can build a high-performance, low-latency, and highly secure Private 5G network to support Industry 4.0, smart manufacturing, and other mission-critical applications.

For more information or to schedule a demo, visit www.canogaperkins.net/syncmetra

About Moso Networks

Moso Networks is a US-based, leading provider of private 5G and neutral host network solutions designed to meet the needs of businesses and industries worldwide. Leveraging its expertise in wireless communication technology, the company delivers secure, reliable, and innovative hardware and management software that empower organizations to unlock the full potential of private 5G connectivity. For more information, visit www.mosonetworks.com.

About Canoga Perkins

Founded in 1963, privately held Canoga Perkins has a long history of providing mission-critical, secure communications to service providers, the military, government agencies, and utilities. With more than 150,000 active network elements operating in Tier 1 service provider networks, Canoga Perkins is differentiated by the telco reliability of its products and its ability to anticipate and nimbly act on emerging IT trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250228986700/en/

Contacts

Amber Flores
aflores@canogaperkins.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release

Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release

Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release

Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye